However, research in this area is still emerging
As with other agents that cause significant weight loss or gastrointestinal fluid losses, there are theoretical class-related risks that warrant attention, including gallbladder disease (cholelithiasis and cholecystitis have been reported with GLP-1 receptor agonists), and dehydration or acute kidney injury in the context of persistent vomiting or diarrhoea
Adequate protein supports the muscle preservation important during weight loss and provides satiety that complements the medications appetite-suppressing effects
No huge surprise, then, that Novo and Eli have popped up as Trumps next targets
Retatrutide + MOTS-c Quick Start The retatrutide + MOTS-c stack pairs two research compounds that work on very different parts of fat metabolism
When prescribed and monitored by a medical professional, both treatments can be very effective